Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.44 |
| ▸ | ABL1 | P00519 | 5/20 | 0.44 |
| ▸ | VCP | P55072 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | YES1 | P07947 | 2/20 | 0.35 |
| ▸ | LYN | P07948 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | PRKACA | P17612 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | FRK | P42685 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.35 |
| ▸ | BLK | P51451 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6997533 | 0.92 | SRC (0.46) | SRCABL1VCPSMN1; SMN2HPGD | |
| SCHEMBL7001342 | 0.80 | SRC (0.45) | SRCSMN1; SMN2EGFRALDH1A1 | |
| SCHEMBL6998124 | 0.77 | SRC (0.55) | SRCABL1VCPSMN1; SMN2HPGD | |
| SCHEMBL7000322 | 0.72 | SRC (0.44) | SRCABL1VCPSMN1; SMN2PSMC4 | |
| SCHEMBL7002224 | 0.72 | SRC (0.44) | SRCABL1VCPSMN1; SMN2HPGD | |
| SCHEMBL6997527 | 0.72 | SRC (0.46) | SRCABL1VCPSMN1; SMN2HPGD | |
| SCHEMBL7003178 | 0.72 | SRC (0.46) | SRCABL1VCPSMN1; SMN2HPGD | |
| SCHEMBL7001439 | 0.70 | SRC (0.44) | SRCABL1VCPHPGDRIPK2 | |
| SCHEMBL7003995 | 0.69 | SRC (0.43) | SRCABL1VCPHPGDRIPK2 | |
| SCHEMBL13019677 | 0.69 | KMT2A (0.49) | SRCABL1SMN1; SMN2HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140938-B1 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | UNIV PRINCETON (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1321467-A2 | High affinity inhibitors for target validation and uses thereof | Princeton University (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | PRINCETON UNIVERSITY | 2003-04-17 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | SRC, MARCKS, TEC | SRC 1/4885ABL1 18/4885VCP 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.